The American Cancer Society has reversed course. Its previous guidance, published in 2010, made no universal recommendation for routine prostate cancer screening and left men at age 50 to use shared decision-making with their doctors. The new guidelines recommend that men at average risk get a PSA test every two years from age 50 to 69, and that men considered high risk, including all Black men, begin yearly testing at 45. That is a clear position, and on balance it is a sound one.
The ACS justifies the change by pointing to new evidence since 2010 that screening saves lives, and by arguing that better case management can avoid the harms of overdiagnosis and overtreatment. The report notes that many men with prostate cancer will never see their disease grow or cause harm, while treatment can bring erectile dysfunction and urinary incontinence. Those harms are real, which is why the guardrails matter as much as the screening recommendation itself.
The guardrails are the most important part of the update. Men are advised to understand the risks and benefits before testing. A high PSA result, defined as 3 ng/mL or higher for men under 70 and 6.5 ng/mL or higher for those 70 and older, should be repeated before any further step. If it stays high, men should get a prostate MRI or a validated biomarker test, and a biopsy should follow only where cancer is strongly suspected. For men diagnosed with low-risk disease, active surveillance is the initial strategy. A screening program that moved straight from a blood test to a biopsy would produce the overtreatment the ACS says it wants to avoid.
The contrast with the federal picture is striking. The US Preventive Services Task Force, whose earlier recommendation was similar to the ACS's 2010 position, is currently working on an update. The report notes that the panel has recently been overhauled by Health Secretary Robert F. Kennedy Jr., and that new members are reportedly rife with conflicts of interest. Whatever the USPSTF decides, patients and clinicians deserve guidance that is transparent about the evidence and free of such doubts.
What should happen next is straightforward. Doctors should walk men through the tradeoffs, insurers should cover the follow-up steps the guidelines call for, and the ACS and federal bodies should publish the evidence behind any future changes. The new guidance gets the balance right: earlier detection for men at higher risk, and restraint for everyone else.